UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of ~~June~~September, 2024

Commission File Number: 001-36619

Affimed N.V.

Gottlieb-Daimler-Straße 2,

68165 Mannheim

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

~~AFFIMED~~Affimed N.V.

~~Annual~~On ~~General~~September 3, ~~Meeting~~2024, ~~Results~~Affimed N.V. (the “Company” or “Affimed”) issued a press release titled “Affimed Appoints Shawn M. Leland as Chief Executive Officer” announcing that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (“CEO”). Dr. Andreas Harstrick, who had been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer.

~~On June 26,~~Except ~~2024~~as stated herein, ~~Affimed~~this ~~N.V.~~report ~~(“Affimed”~~on orForm 6-K shall be deemed to be incorporated by reference into the ~~“Company”)~~registration ~~held~~statements ~~its~~on ~~Annual~~Form ~~General~~F-3 ~~Meeting~~(Registration ofNumber 333-260946), ~~Shareholders~~Form S-8 (~~the~~Registration ~~“2024~~Number ~~AGM”~~333-198812). ~~The~~and ~~final~~Form ~~results~~S-8 (Registration Number 333-270798) of ~~each~~Affimed ofN.V. and to be a part thereof from the ~~agenda~~date ~~items~~on ~~submitted~~which tothis areport ~~vote~~is offiled, to the ~~shareholders~~extent ~~are below.~~not superseded by documents or reports subsequently filed or furnished.

~~Agenda~~Exhibit ~~item~~99.1 3:to ~~Adoption~~this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the ~~Statutory~~Securities ~~Annual~~Exchange ~~Accounts~~Act ~~for~~of 1934 (the ~~financial~~“Exchange ~~year~~Act”) ~~2023~~or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Affimed shareholders approved the adoption of the statutory annual accounts for the financial year 2023.

For		Against		Abstain		Broker Non-Votes
5,711,096		6,641		4,849		0

Agenda item 4: Discharge of the managing directors for their management during the financial year 2023

Affimed shareholders approved the discharge of the managing directors for their management during the financial year 2023.

For		Against		Abstain		Broker Non-Votes
5,201,420		399,482		121,684		0

Agenda item 5: Discharge of the supervisory directors for their supervision during the financial year 2023

Affimed shareholders approved the discharge of the supervisory directors for their supervision during the financial year 2023.

For		Against		Abstain		Broker Non-Votes
5,414,015		287,837		20,734		0

Agenda item 6(a): Reappointment of Dr. Andreas Harstrick as a managing director

Affimed shareholders approved the reappointment of Dr. Andreas Harstrick as a managing director.

For		Against		Abstain		Broker Non-Votes
5,548,623		33,159		140,804		0

Agenda item 6(b): Reappointment of Dr. Wolfgang Fischer as a managing director

Affimed shareholders approved the reappointment of Dr. Wolfgang Fischer as a managing director.

For		Against		Abstain		Broker Non-Votes
5,544,920		51,107		126,559		0

Agenda item 6(c): Reappointment of Ms. Denise Michele Mueller as a managing director

Affimed shareholders approved the reappointment of Ms. Denise Michele Mueller as a managing director.

For		Against		Abstain		Broker Non-Votes
5,513,920		81,694		126,972		0

Agenda item 8: Increase authorized share capital; Amendment of the articles of association

Affimed shareholders approved the proposal to increase authorized share capital; amendment of the articles of association.

For		Against		Abstain		Broker Non-Votes
5,216,584		461,983		44,019		0

Agenda item 9(a): Authorization of the Management Board to issue shares and/or grant rights to subscribe for shares

Affimed shareholders approved the authorization of the Management Board to issue shares and/or grant rights to subscribe for shares.

For		Against		Abstain		Broker Non-Votes
4,645,145		1,032,223		45,218		0

Agenda item 9(b): Authorization of the Management Board to restrict and/or exclude pre-emptive rights in connection with agenda item 9(a)

Affimed shareholders approved the authorization of the Management Board to restrict and/or exclude pre-emptive rights in connection with agenda item 9(a).

For		Against		Abstain		Broker Non-Votes
4,664,367		1,023,340		34,879		0

Agenda item 10: Cancellation of shares

Affimed shareholders approved the cancellation of shares.

For		Against		Abstain		Broker Non-Votes
4,843,558		50,084		828,944		0

Agenda item 11: Appointment of the auditor for the financial year 2024

Affimed shareholders approved the appointment of the auditor for the financial year 2024.

For		Against		Abstain		Broker Non-Votes
5,707,458		8,777		6,351		0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AFFIMED N.V.
Date: June 26, 2024	By:	/s/ Andreas Harstrick
Date: September 3, 2024	By:	/s/ Andreas Harstrick
	Name: Andreas Harstrick
	Title: Acting Chief Executive Officer, Chief Medical Officer
	Title: Chief Medical Officer
	By:	/s/ Denise Mueller
	Name: Denise Mueller
	Title: Chief Business Officer

EXHIBIT INDEX


Exhibit		Description of Exhibit

99.1		Affimed N.V. Press Release dated September 3, 2024.

Filing Compare · Affimed N.V.